Added to YB: 2026-07-13
Pitch date: 2026-07-09
TENX [bullish]
Tenax Therapeutics, Inc.
-3.31%
current return
Author Info
No bio for this author
Company Info
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Market Cap
$896.7M
Pitch Price
$18.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-12.54
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Tenax Therapeutics ($TENX): A High-Conviction Binary Bet on Oral Levosimendan Ahead of the LEVEL Readout
TENX: Binary long on oral levosimendan in PH-HFpEF, topline Aug. +300%/-80% setup. Base case ~60% PoS vs consensus ~40%. Thesis: HELP 'miss' was trough artifact; venodilation decongests (EF-independent), +29m 6MWD with flat CO. LEVEL enriches responders, continuous TID dosing, post-COVID clean conduct. Multibillion mkt, zero approved therapies. Win = M&A takeout. FD mcap ~$750m, EV ~$630m. Risks: REBALANCE null, small n=37, placebo drift.
Read full article (5 min)